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Background: The objective of this study was to evaluate the impact of rheumatoid arthritis (RA) on patients’
sexuality and identify disease and other factors such as fatigue that most influence sexual relationships.
Methods: A specific pretested questionnaire was sent to all members of a French patient association (ANDAR).
Questions related to demographics, disease status, quality of life (utility, EQ-5D), pain, psychological status (mood),
fatigue and emotional and sexual relationships. To isolate the impact of RA, an attempt was made to include a
matched sample from the general population.
Results: The analysis included 1271 patients, but only 70 controls agreed to participate and comparisons should
therefore be considered with caution. The two groups were similar in terms of age, gender distribution, living
conditions and diseases other than RA. However, patients scored worse for global health, mood, fatigue, had a
lower utility (0.55 versus 0.65). Controls were more active sexually (69% versus 63%), in particular women (71%
versus 60%). Age, gender, living alone, physical function and mood were significant predictors for being sexually
active for patients; for controls, age and overall quality of life (utility) were significant predictors.
Conclusions: While it is known that RA has a negative impact on patients’ sexuality, there have been few attempts
to quantify the problem. Our study highlights the negative impact of RA on patients’ sexuality, and triggers the
question how to include this aspect into care.
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Rheumatoid Arthritis (RA) was one of the first diseases
where quality of life (QoL) measurements were included
in clinical trials in the mid-eighties [1]. Today investigat-
ing patient-reported outcomes has become standard in
clinical research and a number of measures are routinely
included in trials [2].
Yet, with ever more effective anti-inflammatory and
disease modifying treatments available to the treating
rheumatologist, the focus in clinical practice is more on
control of those objectively measurable disease symp-
toms such as disease activity targeted by these treat-
ments than on the more subjective and less obvious
parts of patients’ well-being. While the relationships* Correspondence: Gisela.kobelt@he-europe.com
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reproduction in any medium, provided the orbetween QoL and inflammation, pain and functional
limitations have been shown [3-5], control of these
symptoms may not fully restore all physical, social and
mental aspects of QoL. Studies in France on these topics
are rare. The international literature provides an over-
view of issues such as fatigue, depression, sleep disorder,
coping [6-11] and social interactions, family life and
sexuality [12-15]. In a survey among French patients
around half answered that RA impacted negatively on
their family life and/or sexuality [16]. In another obser-
vational study in France 80% of patients spontaneously
reported fatigue as the most difficult aspect to cope with
in daily life, while 15% indicated problems with sexuality
[17].
The objectives of the current study were therefore to
investigate the impact of RA on patients’ intimate and
sexual relationships and identify significant factors such
as functional handicap, pain and in particular fatigueLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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blems caused by RA, the study attempted to include a
control group from the normal population.
Methods
Study approach and subjects
The study was performed as a mail survey addressed to
all members of a French patient association (Association
Nationale de Défense contre l’Arthrite Rhumatoïde,
ANDAR). The control group was enrolled via a second
mailing to a random sample of 600 ANDAR members
requesting them to ask an acquaintance of similar age
and gender to participate. Both groups were adults and
provided written consent to participate in the study.
At the time of the study, ethical approval was not
required for surveys carried out by patient organisations
with their own members, provided informed consent is
received from participants. However, the study protocol
and questionnaire were submitted to the Commission
Nationale d’Information et de Liberté (CNIL) for
approval.
Data
The patient questionnaire was developed by a team of
specialists including rheumatologists, a sexologist and
patients, and pretested for clarity and relevance in two
rounds with two different groups of patients. Questions
concerned
– demographic data (current): age, gender, family
situation, education, professional activity and level of
family income
– disease data (current, past week): presence of co-
morbidity, disease duration, general health status
(global visual analogue scale, VAS), functional status
(HAQ) [18], disease activity (VAS), pain (VAS) as
well as mood (VAS).
– utility (current): EQ-5D [19], a generic preference
based questionnaire addressing five domains of
general well being (mobility, pain, self-care, usual
activities, anxiety/depression).
– fatigue (past week, past 6 months): VAS as well as a
validated French fatigue scale (Pichot) [20] followed
by questions on the (self-assessed) causes and the
impact of fatigue, coping mechanisms and medical
help
– sexuality (past 12 months): self-assessed impact of
RA, sexual activity and reasons for inactivity,
specific difficulties and coping mechanisms,
repercussions and medical support
The questionnaire for controls contained the same
questions except for disease variables (duration, HAQ,
disease activity, pain). For fatigue, only the VAS was usedto keep the questionnaire short, and questions relating
to possible causes for sexual inactivity (e.g. personal pro-
blems, bad health) were modified with the help of a
sexologist.
Analysis
Answers were fully anonymous and returned directly to
the data management centre in prepaid envelopes. Thus
no verification was possible and questionnaires with
missing demographic or disease data or containing inad-
equate remarks were excluded. We performed basic de-
scriptive analyses on all quantitative and qualitative
variables and stepwise logistic and linear multiple




Within 2 months 1314 patient questionnaires were
returned (38%) and 1271 could be included in the ana-
lysis. Respondents were from all geographic regions,
with a response rate above 30% in all areas; the largest
samples were in urban areas (Lyon, Paris) and Southern
France. For the control group, response rate was as
expected lower (12%) and all 70 responses were included
in the analysis. Overall, controls were similar to the pa-
tient group in terms of geographic distribution, mean
age, gender, education and household income. However,
the sample was small and in particular male respondents
were few and they appeared to be in poor health. Com-
parisons should therefore be made with caution and
focus more on women.
The characteristics of the two samples are shown in
Table 1. The level of education was similar to the French
population with ~70% having completed the second cycle
(“baccalauréat” or professional diploma) [21] and ~25%
with higher education [22]. The proportion of patients
working was significantly lower than for controls and the
level of professional activity in France. Income distribution
was however not significantly different from the general
population for both samples [23].
Health Data
Health data for both samples are presented in Table 2.
The presence of diseases other than RA was similar be-
tween patients and controls (61.5% versus 59%), with,
however, a difference for women (62% versus 54%).
The mean/median disease duration was 19.0/18
(SD11.6) years, but 24% had the diagnosis since less than
10 years. This corresponds well to the age structure in
the patient association. Mean and median HAQ was
1.25; 20% of patients had a score above 2, and 56% and
58% used technical aides or medical devices, respect-
ively. Almost all patients were on disease modifying
Table 1 Characteristics of the sample
Patients Controls
Sample Men Women Sample Men Women
N, %, mean N, %, mean N, %, mean N, %, mean N, %, mean N,%, mean
N 1268 200 (16%) 1068 (84%) 70 16 (23%) 54 (77%)
Age (mean) 63.8 (12.4) 66.1 63.3 60.4 (11.7) 63.1 59.6
Living alone 28% 11%* 31%* 24% 31% 25%
Respondents < 60 422 (33%) 58 (29%) 364 (34%) 31(44%) 5 (31%) 26 (48%)
Proportion <60 working 55.0% 58.6% 54.4% 74.2%** 60.0% 76.9%
Proportion <60 on full/partial invalidity 45.3% 45.6% 47.8% - - -
Respondents education 1163 (92%) 64 (92%)
Basic 29.8% 34.4%
Professional diploma 18.5% 17.2%
High school 23.7% 21.9%
University 28.0% 26.6%





Respondents sexuality 1134 (89%) 192 (96%) 942* (88%) 70 (100%) 16 (100%) 54 (100%)
Sexually active 63% 76% 60%* 69% 63% 71%
<55 years 85% 91% 85% 86% 75% 89%
55-65 years 66% 91% 62%* 76%** 75% 76%
>65 years 36% 57% 32%* 54%** 50% 56%



















Table 2 Summary disease data
Patients Controls
Sample Men Women Sample Men Women
Mean (SD), % Mean (SD), % Mean (SD), % Mean (SD), % Mean (SD), % Mean (SD), %
N 1268 200 1068 70 16 54
% with disease other than RA 61.5% 60% 62% 59% 75% 53.7%
Disease duration 19.0 (11.6) 16.6 19.5 - - -
HAQ 1.2 (0.8) 0.9 1.3* - - -
Disease activity (VAS) 4.6 (2.2) 4.1 4.7 - - -
Pain (VAS) 4.7 (2.2) 4.2 4.7* - - -
Biologic treatment 40.8% 35.4% 42.2%* - - -
Global Health (VAS) 4.5 (1.9) 4.3 4.5 3.8 (2.2)** 3.7 3.8
Fatigue (VAS) 5.6 (2.2) 4.9 5.7 5.3 (2.4) 5.1 5.5
Mood (VAS) 4.2 (2.2) 4.0 4.2 3.9 (2.1) 4.4 3.8
Utility 0.55 (0.3) 0.61 0.54 0.65 (0.3)** 0.57 0.68
*p < 0.01 (gender), **p < 0.01 (controls versus patients).
All VAS = 1(best)-10(worst); Pichot scale = 0(best)-32(worst); HAQ=Health Assessment Questionnaire; SD= standard deviation.
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more frequently in this sample than the national average
estimated at 15% in 2008 [24].
Mean scores on the different VAS (1-10 worst) were
generally worse for patients than for controls. Similarly,
utility scores for patients (mean/median 0.55/0.66) were
lower than those of controls (0.65/0.72) and the general
population between 60 and 70 (~0.80) [25]. For patients,
the largest impact of RA was seen in the domains pain
(95% with moderate/severe pain compared to ~45% in
the general population), anxiety/depression (67% with
moderate/severe problems compared to ~30%) and usual
activities (64% with moderate or severe difficulties com-
pared to ~10%) 25. Overall, women had worse disease
and worse utility, but judged their overall health better
than men.Table 3 Fatigue
Patients
Fatigue<= 4 F
Respondents 1166 349 (30%) 81
Age 62.8
Disease duration (years) 18.1
Working (%) 24.3%
% on Biologics 45.5%
HAQ 0.8
Disease activity 3.1




*p < 0.01 high versus low fatigue.
All VAS including fatigue = 1(best)-10(worst); Utility 0(death)-1(full health); HAQ=HeFatigue
Fatigue was an issue for both patients and controls: only
30% of patients and 25% of controls had a score on the
VAS of 4 or below (Table 3). Patients with more fatigue
were not significantly different in terms of age and dis-
ease duration, but appeared to have more severe disease
(HAQ, disease activity, pain), lower workforce participa-
tion and significantly lower utility. There was a trend for
patients at higher education and income levels to have
better scores on both fatigue scales. Professionally active
patients had less severe disease and thus also less fatigue.
A trend for less fatigue was also seen in patients on bio-
logic treatment. On the Pichot fatigue scale (0-32 worst),
patients had a mean/median of 17.2/18; 39.4% had
scores indicative of a pathological fatigue (>20) while 9%
had severe fatigue (>27). In stepwise multiple regressionControls
atigue> 4 Fatigue<= 4 Fatigue> 4












Table 4 Impact of RA on personal and intimate (sexual) relationships
Impact of RA
Emotional relationships Intimate relationships
Mean Mean
RA negative RA no effect RA negative RA no effect
N 763 354 834 270
Age 61.0* 65.2 60.8* 66.6
HAQ 1.3* 1.0 1.3* 0.9
Fatigue (VAS) 5.8* 4.9 5.8* 4.9
Pain (VAS) 4.7 4.2 4.7 4.2
Disease Activity (VAS) 4.9* 3.9 4.8* 3.9
Mood (VAS) 4.5* 3.3 4.3* 3.4
Utility 0.605* 0.647 0.592* 0.511
*p < 0.01 negative effect/no effect.
All VAS = 1(best)-10(worst); Utility 0(death)-1(full health); HAQ=Health Assessment Questionnaire.
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together with age and mood explained a significant part
of fatigue.
The cause most often cited for fatigue was RA (77.1%)
and sleep disturbances (47.4%), and over half of the
patients (51.6%) had reduced or stopped leisure activities
while 47% felt discouraged. Most patients (59%) coped
with fatigue by resting in the afternoon and more than
half cited their family as their best support. Three quar-
ters of patients had addressed the issue with their phys-
ician and also felt that rheumatologists and
physiotherapists were adequately aware of the issue,
while employers appeared to lack understanding (60%).
Sexuality
The majority of patients felt RA to be an obstacle for in-
timate and sexual relationships (68% and 76%,Table 5 Impact of RA on sexual activity by age group







N 712 (62%) 425 226 (78%) 63 240 (60%)
Age 59.1 67.9* 55.5 56.6 64.
HAQ 1.0 1.5* 1.0 1.30* 1.
Disease Activity 4.3 5.0* 4.4 4.9 4.
Pain 4.3 5.1* 4.4 4.6 4.
Global health 4.2 4.7* 3.3 3.6 3.
Fatigue 5.3 6.0* 5.3 5.9* 4.
Mood 3.9 4.6* 4.1 4.7 3.
Utility 0.61 0.49* 0.59 0.51 0.
Sexual satisfaction 5.4
*p < 0.01 not active/active within group.
All VAS = 1(best)-10(worst); Utility 0(death)-1(full health); HAQ=Health Assessment Qrespectively); for 29% and 33%, respectively, it was a
major obstacle. Patients who indicated a strong negative
impact of RA were younger but had overall more severe
disease (Table 4). Among controls, only 38% (25% of
women) felt that they faced obstacles for their sexual
relationships.
Table 5 summarizes results about sexual activity for
both samples and by age groups. Among patients, 63%
were sexually active during the past 12 months (60%
among women, 76% among men), compared to 69% of
controls. For patients not sexually active (N= 425), RA
was the main reason (31%) followed by other diseases
(8%), while controls (N= 22) indicated personal reasons
(73%) and poor health (64%). It is thus not surprising
that patients and controls who were sexually active were
in better health and had a higher utility. Differences be-
tween patients and controls were most striking ins 60-70 Controls Controls 50-60 Controls 60-70









163 48 (69%) 22 15 (75%) 5 15 (71%) 6
5 65.1 57.7 66.2* 53.1 54.8 63.7 63.2
00 1.5* - - - - - -
1 5.0* - - - - - -
1 5.0* - - - - - -
9 4.7 3.3 4.2* 3.6 3.0 3.1 6.0*
8 6.0* 5.4 5.2 5.4 4.2 5.7 6.5*
4 4.7* 3.6 4.7* 3.7 3.4 3.0 7.0*
63 0.52* 0.74 0.45* 0.75 0.38 0.80 0.51*
5.9
uestionnaire.
Table 6 Logistic regression model, sexual activity
p< Odds ratio 95% C.I. for Odds ratio
Lower Upper
Gender (M= 1,F = 0) ,018 1,832 1,109 3,026
Living alone ,000 ,276 ,187 ,408
age ,000 ,942 ,926 ,959
HAQ ,001 ,639 ,497 ,823
mood ,001 1,154 1,062 1,254
Constant ,000 80,654
Dependent variable: being sexually active. Independent variables tested with
stepwise exclusion: age, gender, living alone, education level, income level,
professional activity,early retirement due to RA, comorbidity, fatigue, pain,
disease activity, HAQ, biologic treatment, mood and utility. Significant effects
were found for age, gender, living alone, mood and HAQ: older patients,
women, patients living alone, patients with depressed mood and those with a
higher HAQ were less likely to be sexually active.
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disease has progressed: only 32% of female patients over
65 were active compared to 56% in controls.
In step-wise logistic regression analysis, higher age, liv-
ing alone, worse HAQ, lower spirits (mood) and being
female had a significant negative impact on whether
patients were sexually active. (Table 6) For couples,
higher HAQ, higher age and lower spirits (mood) were
significant predictors; for patients living alone predictors
were age and being a woman. Only one study has identi-
fied a similar impact of function, mood and age on sex-
ual activity, although in that study fatigue also was
significant [14].
Only 42% of patients indicated that they used devices,
drugs or therapy related to their sexual problems. Re-
gardless of whether they were sexually active or not, all
cited essentially the same reasons for difficulties with or
absence of sexual relationships (absence of desire, vagi-
nal dryness, joint pain) and the same consequences
(guilt feelings, frustration, tensions with the partner).
Very few patients had discussed the issue with a health
professional (18.6%), most of them with either their gen-
eral practitioners or the gynecologist. Among patients
who had not addressed the issue, two thirds did not
want to discuss it with a professional and did not feel
that they needed support. Controls appeared to find it
easier to address the issue with 70% of men and 42% of
women having discussed with a health professional.
Discussion and conclusions
Difficulties in sexual relationships have been mentioned
in surveys among patients with RA as an aspect of the
disease that is difficult to cope with. However, no study
has investigated this in depth in France and the French
patient association ANDAR thus decided to perform a
specific study on RA patients’ sexuality. Research on fa-
tigue – which is also often mentioned as a very difficult
and handicapping aspect of RA - was primarily includedbecause of a hypothesis that fatigue would negatively im-
pact on sexual activity. The results in our study indicate,
however, that the impact is not significant. We would
argue that the reason for this is the strong impact of
physical function (HAQ) which is a significant predictor
for having sexual activity or not, but is also correlated
with fatigue.
However, with a relatively scattered picture of research
on fatigue in RA patients, fatigue is also interesting as a
research topic in its own right. Indeed, fatigue was sig-
nificantly correlated with most disease variables col-
lected in the study: patients with higher fatigue scores
had also a higher HAQ, higher disease activity, worse
general health, worse pain, more depressed mood and
worse quality of life (utility). Among these, HAQ was a
strong driver of fatigue, with scores around 3-4 at low
HAQ levels to 7 at higher HAQ levels. This confirms
the correlation between HAQ and fatigue as reported by
patients in an earlier survey [17], but other data on this
relationship are scarce. A British study reported similar
proportions of patients with fatigue (80%), but found
that fatigue reflected pain and signs of depression, not
disease activity; functional status was not investigated
[9].
An interesting finding was that patients who were
working were less fatigued than those working, but also
had a lower HAQ. Thus, fatigue and HAQ together have
a significant impact on whether a patient can remain in
the workforce or not. Contrary to this, controls who
were working had significantly more fatigue than those
not working. Fatigue may thus be simply a consequence
of working for a population in this age group, but one of
drivers of being able to work or not for patients.
Previous experience with patient surveys in France
indicates answer rates between 30% and 50%. In light of
this, and the delicate subject, the overall answer rate of
38% in this survey, with a 90% completion rate for the
part sexuality appears excellent and indicative of the im-
portance of this topic to patients. However, the size of
the problem is difficult to assess without a comparator
group – and such a group is difficult to study, with the
limited means of a patient association. We therefore
decided to ask a random group of patients to hand the
questionnaire to an acquaintance of theirs. The hypoth-
esis that this would provide a sample with similar char-
acteristics as the patients proved correct, although the
low number of respondents (12%) was somewhat of a
disappointment. Nevertheless, we believe that even the
small control group provides insights into the part
played by RA in sexual difficulties.
Controls and patients were similar in their demo-
graphics, but controls had a surprisingly high number of
diseases (59% with an average of 1.1 diseases). This is
only slightly less than the co-morbidities of the patients
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we can assume that this exerts a similar effect in both
groups. Significantly fewer patients below 60 (the official
retirement age in France) were working than controls,
55% versus 74%, and we would argue that RA is the
cause for this difference.
More controls were sexually active, but the difference
was small in the population below 55 years. This appears
logical, as at that age many patients still have relatively
mild RA (mean HAQ 0.97 compared to 1.31 above 55).
However, the difference becomes significant at ages
above 55: 10-20% fewer patients have sexual activities,
with the differences particularly striking for women. As
potential issues with age and menopause cannot be dif-
ferent between the two female groups, this difference
can thus be considered to be due to RA. Only one other
study on sexual activity included a control group [15]
and findings were similar.
Few individuals had addressed the issues with a health
professional (36% of controls and 18.5% of patients) and
those who hadn’t discussed it, were reluctant to do so.
However, as more research into this topic is performed,
arguments in favor of a more open dialogue between
patients and treating physicians might emerge [26].
Our patient sample may, although it is representative
of the structure of the patient association, not be entirely
representative of the overall RA population in France.
Members of patient associations are often older, with
longer disease duration and possibly more severe dis-
ease, as it takes time before they join. Another issue
appears to be the more frequent than average treatment
with biologics in the sample. This can likely be partly
explained by the longer disease duration and hence
advanced disease with patients having failed a number of
DMARDs over time. It is also possible that patients on
biologics are more aware of issues and more motivated
to participate in surveys. A similar picture had emerged
in the earlier economic survey performed by ANDAR
[17]. This does in our view not diminish the value of the
information obtained from the sample.
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